Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV ...
Merck issued guidance for 2025 that lags consensus ... after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine in China overshadowed a quarterly earnings beat.
a vaccine that prevents cancer from HPV, into China beginning in February through and going through at least mid-2025. Merck reported fourth-quarter revenue and adjusted earnings that topped ...